Carlos Fernández‐Carrillo

ORCID: 0000-0002-1326-5142
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Liver Disease Diagnosis and Treatment
  • Liver Disease and Transplantation
  • Hepatitis C virus research
  • Alcohol Consumption and Health Effects
  • Hepatitis B Virus Studies
  • Systemic Lupus Erythematosus Research
  • COVID-19 Clinical Research Studies
  • Hepatocellular Carcinoma Treatment and Prognosis
  • COVID-19 and healthcare impacts
  • Bariatric Surgery and Outcomes
  • Organ Transplantation Techniques and Outcomes
  • Long-Term Effects of COVID-19
  • Esophageal and GI Pathology
  • Diet and metabolism studies
  • Nutrition and Health in Aging
  • RNA Research and Splicing
  • Liver Diseases and Immunity
  • HIV Research and Treatment
  • SARS-CoV-2 detection and testing
  • Kawasaki Disease and Coronary Complications
  • Pancreatitis Pathology and Treatment
  • Lipid metabolism and disorders
  • Body Composition Measurement Techniques
  • Esophageal Cancer Research and Treatment
  • Biochemical effects in animals

University of Pittsburgh Medical Center
2021-2024

Hospital Universitario Puerta de Hierro Majadahonda
2013-2024

Centro de Investigación Biomédica en Red
2014-2024

Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas
2013-2024

Centre for Biomedical Network Research on Rare Diseases
2024

Instituto de Salud Carlos III
2016-2022

Center for Digestive and Liver Diseases
2022

University of Leeds
2021

University of Pittsburgh
2018

Hospital Clínic de Barcelona
2013-2017

Direct-acting antiviral agents (DAAs) are highly effective and well tolerated in patients with chronic hepatitis C virus infection, including those compensated cirrhosis. However, fewer data available more advanced liver disease. Our retrospective, noninterventional, national, multicenter study from the Spanish Hepa-C registry investigated effectiveness safety of interferon-free DAA regimens disease, decompensated cirrhosis, routine practice (all currently approved were registered). Patients...

10.1002/hep.29097 article EN publisher-specific-oa Hepatology 2017-02-07

INTRODUCTION: Several scoring systems predict mortality in alcohol-associated hepatitis (AH), including the Maddrey discriminant function (mDF) and model for end-stage liver disease (MELD) score developed United States, Glasgow alcoholic Kingdom, age, bilirubin, international normalized ratio, creatinine Spain. To date, no global studies have examined utility of these scores, nor has MELD-sodium been evaluated outcome prediction AH. In this study, we assessed accuracy different scores to...

10.14309/ajg.0000000000001596 article EN The American Journal of Gastroenterology 2021-12-28

INTRODUCTION: The effect of branched-chain amino acid (BCAA) supplementation on muscle mass in patients with cirrhosis and sarcopenia is unknown. METHODS: This a pilot, prospective, randomized, double-blind study cohort 32 diagnosed by computed tomography scan who underwent nutritional physical activity intervention for 12 weeks. They were divided into 2 groups (placebo: 17 patients; BCAA: 15 patients). protocol was registered at ClinicalTrials.gov (NCT04073693). RESULTS: Baseline...

10.14309/ajg.0000000000001301 article EN The American Journal of Gastroenterology 2021-05-26

Abstract Background COVID-19 is a potentially severe disease caused by the recently described SARS-CoV-2. Whether liver fibrosis might be relevant player in natural history of currently unknown. We aimed to evaluate association between FIB-4 and risk progression critical illness middle-aged patients with COVID-19. Methods In this multicenter, retrospective study prospective follow-up 160 aged 35–65 years COVID-19, FIB-4, clinical, biochemical variables were collected at baseline. ≥2.67...

10.1093/infdis/jiaa355 article EN other-oa The Journal of Infectious Diseases 2020-06-16

Abstract Background and Aim The aim was to validate noninvasive methods predict the presence of gastroesophageal varices (GEV) in patients with suspected compensated advanced chronic liver disease. Methods We retrospectively reviewed clinical radiological data collected prospectively between September 2013 2015. 442 consecutive disease measured by transient elastography (TE) a gastroscopy. evaluated platelets, spleen diameter, TE, stiffness × size/platelets (LSPS), variceal risk index (VRI),...

10.1111/jgh.13781 article EN Journal of Gastroenterology and Hepatology 2017-03-11

Objective Alcohol-related liver disease (ALD) ranges from never-decompensated ALD (ndALD) to the life-threatening decompensated phenotype, known as alcohol-related hepatitis (AH). A multidimensional study of clinical, histological and molecular features these subtypes is lacking. Design Two large cohorts patients were recruited in an international, observational multicentre study: a retrospective cohort with ndALD (n=110) prospective AH (n=225). Clinical, analytical, immunohistochemistry...

10.1136/gutjnl-2021-324295 article EN Gut 2022-01-06

Abstract Background/Aims Bariatric surgery can increase the risk of addictive disorders and nutritional deficiencies. The aim this study was to evaluate association between bariatric alcohol use disorder (AUD), alcohol-related liver disease (ALD), psychiatric associated with AUD. impact vitamin D deficiency in these associations also investigated. Methods A cross-sectional performed using National Inpatient Sample database its ICD-9 codes information. Diagnostic comorbidity data from...

10.1007/s11695-023-06490-w article EN cc-by Obesity Surgery 2023-03-07

Risk of alcoholic cirrhosis is determined by genetic and environmental factors. We aimed to investigate if climate has a causal effect on alcohol consumption its weight cirrhosis. collected extensive data from 193 sovereign countries as well 50 states 3,144 counties in the United States. Data sources included World Health Organization, Meteorological Institute Metrics Evaluation. Climate parameters comprised Koppen‐Geiger classification, average annual sunshine hours, temperature. Alcohol...

10.1002/hep.30315 article EN Hepatology 2018-10-16

Summary Patients with HCV genotype 3 (GT3) infection and cirrhosis are currently the most difficult to cure. We report our experience sofosbuvir+daclatasvir (SOF+DCV) or sofosbuvir/ledipasvir (SOF/LDV), without ribavirin (RBV) in clinical practice this population. This was a multicenter observational study including cirrhotic patients infected by GT3, treated sofosbuvir plus an NS5A inhibitor (May 2014‐October 2015). In total, 208 were included: 98 (47%) treatment‐experienced, 42 (20%)...

10.1111/jvh.12648 article EN Journal of Viral Hepatitis 2016-12-09

Abstract Background and Aim Significant human material resources have been diverted to coronavirus disease 2019 (COVID‐19). Healthcare workers are at high risk of severe acute respiratory syndrome 2 (SARS‐CoV‐2) infection. We assess the impact COVID‐19 pandemic on gastroenterology hepatology departments specialists in Spain. Methods This study involves a nationwide survey addressing resources, procedures, physicians 81 hospitals representative Spanish National Health Service. Results...

10.1111/jgh.15340 article EN Journal of Gastroenterology and Hepatology 2020-11-13

Abstract Background and Aims Transient elastography (TE) to estimate liver stiffness has proved be very useful in the diagnosis of chronic disease. Here, we intend evaluate its use a large Spanish cohort. Method Nested study within PREVHEP‐ETHON (Epidemiological sTudy Hepatic infectiONs; NCT02749864) population‐based, cross‐sectional performed between July 2015 April 2017. An epidemiological questionnaire, laboratory tests TE anthropometric measurements were obtained. Results Data from...

10.1002/ueg2.12109 article EN cc-by-nc-nd United European Gastroenterology Journal 2021-06-02

Background and Aims: Alcohol use disorder has been reported in patients undergoing bariatric procedures, but the pattern of alcohol consumption not evaluated. We investigated prevalence, risk factors, impact binge drinking (BD) at time surgery during follow-up. Methods: A prospective, longitudinal study subjects was included LABS-2 registry between 2006 2009. Participants with AUDIT questionnaire a minimum 12 months follow-up were included. BD defined as consuming ≥5 drinks on least 1...

10.1097/hc9.0000000000000490 article EN cc-by-nc-nd Hepatology Communications 2024-07-22

Abstract Aim Non‐malignant portal vein thrombosis (PVT) is a complication of liver cirrhosis. The aim this study was to evaluate the annual incidence PVT and related risk factors. Methods We retrospectively reviewed clinical, laboratory, radiological data collected prospectively from September 2016 2017. A follow‐up 36 months performed in subset patients determine cumulative complications. Results included 567 patients. at 12, 24, 3.7%, 0.8%, 1.4%, respectively. Patients with were compared...

10.1111/hepr.13703 article EN Hepatology Research 2021-07-29

Background: Central obesity, due to the accumulation of visceral fat(VF), is one main risk factors for venous thrombosis. The aim this study was determine if VF may be a factor development portal vein thrombosis(PVT) in cirrhotic patients.Methods: A total 214 patients at outpatient clinic were consecutively included, undergoing an anthropometric evaluation, blood tests and bioimpedance.Results: Median MELDscore was10. Prior liver decompensation occurred 44.9% 35.6% had large esophageal...

10.1080/17474124.2019.1651644 article EN Expert Review of Gastroenterology & Hepatology 2019-08-08

Guidelines recommend that patients with hepatitis C virus (HCV)-related liver disease be treated for HCV before transplant (LT) to eliminate the surgery. However, unpredictability of donor organ availability may limit treatment duration. Interruption resumption post-LT is 1 potential solution which has not been investigated widely.Patients from 5 clinical centers included in large, national, noninterventional Hepa-C registry who started direct-acting antiviral agents while awaiting LT were...

10.1097/tp.0000000000001596 article EN Transplantation 2016-12-01
Coming Soon ...